SomaLogic and Korea’s DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics market
19 Setembro 2023 - 5:30PM
SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics
technology, today announced its partnership with DNA Link, an
innovator in personalized and precision medicine, to offer the
7,000-plex SomaScan® platform to their customers. DNA Link will be
the first SomaLogic authorized site in Korea.
“Over the past 20 years, DNA Link has cultivated a reputation
for generating and interpreting high-quality genomic data,” said
Chief Executive Officer of DNA Link, Lee Jong-eun. “By bringing
expanded proteomics capabilities through SomaLogic to our
offerings, we can add to our abilities in biomarker discovery and
drug development in Korea and across Asia, ultimately contributing
to improving human health and quality of life.”
SomaLogic’s 7,000-plex SomaScan assay will significantly expand
DNA Link’s proteomics capabilities in its laboratory in Seoul,
Korea. DNA Link has been conducting genomics research from its labs
for more than two decades with a focus on genetic epidemiology,
drug development and personalized medicine. Their multiomics
offerings are available in Korea and across Asia.
DNA Link joins Biostar in China, Molecular Genomics in Singapore
and FonesLife in Japan as SomaLogic authorized sites in the APAC
region.
“Korea is a major contributor to the fast-growing proteomics
market in the Asia Pacific region due to an increase in research
funding, especially around personalized therapeutics and the
growing awareness of proteomics technology and what it can offer,”
said SomaLogic Chief Executive Officer Adam Taich. “We’re looking
forward to supporting DNA Link in expanding the use of proteomics
for research in this region.”
For more than twenty years, SomaLogic has grown from its roots
in the research lab to become a global leader in proteomics with
technology that delivers the quality and quantity of biological
insights life science researchers need - from lab to last mile.
About SomaLogic SomaLogic is catalyzing
drug research and development and biomarker identification as a
global leader in proteomics technology. With a single 55 microliter
plasma or serum sample, SomaLogic can run 7,000 protein
measurements, covering more than a third of the approximately
20,000 proteins in the human body. For more than 20 years we’ve
supported pharmaceutical companies, and academic and contract
research organizations who rely on our protein detection and
analysis technologies to fuel drug, disease, and treatment
discoveries in such areas as oncology, diabetes, and
cardiovascular, liver and metabolic diseases. Find out more at
somalogic.com and follow @somalogic on LinkedIn.
Forward Looking Statements This press
release contains certain forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
All statements, other than statements of historical fact included
in this press release, regarding our strategy, future operations,
financial position, estimated revenues, projections, prospects,
plans and objectives of management are forward-looking statements.
These forward-looking statements generally are identified by the
words “believe,” “project,” “forecast,” “guidance,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“continue,” “will likely result,” “possible,” “potential,”
“predict,” “pursue,” “target” and similar expressions, although not
all forward-looking statements contain such identifying words.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Forward-looking statements do not guarantee
future performance and involve known and unknown risks,
uncertainties and other factors. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including factors which are
beyond SomaLogic’s control. You should carefully consider these
risks and uncertainties, including, but not limited to, those
factors described under Part I, Item 1A – “Risk Factors” in our
Annual Report on Form 10-K and other filings we make with the
Securities and Exchange Commission. These filings identify and
address important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and SomaLogic assumes
no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Should one or more of these risks or
uncertainties materialize, or should any of the assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. The Company will not
and does not undertake any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws.
SomaLogic Media Contact Emilia Costales
720-798-5054 ecostales@somalogic.com
SomaLogic Investor ContactMarissa
BychGilmartin Group LLCinvestors@somalogic.com
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
SomaLogic (NASDAQ:SLGC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024